Agree.
Recent ALNY News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 08:20:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 08:18:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 08:16:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 08:12:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 08:11:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 08:08:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 08:06:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 08:04:48 PM
- Alnylam Issues 2025 Corporate Responsibility Report • Business Wire • 05/19/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:17:02 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/14/2026 05:55:35 PM
- De nouvelles analyses de données présentées lors du congrès Heart Failure 2026 démontrent les bénéfices cliniques solides et constants du vutrisiran en tant qu’option thérapeutique de première intention chez toutes les populations • Business Wire • 05/13/2026 07:53:00 PM
- Heart Failure 2026: Neue Datenanalysen belegen robusten und konsistenten klinischen Nutzen von Vutrisiran als Erstlinien-Behandlungsoption für ATTR-CM-Patientenpopulationen – auch bei hoher Krankheitslast • Business Wire • 05/13/2026 06:28:00 PM
- New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden • Business Wire • 05/12/2026 06:30:00 AM
- Alnylam to Webcast Presentations at Upcoming Investor Conferences • Business Wire • 05/07/2026 12:00:00 PM
- Alnylam präsentiert auf der „Heart Failure 2026“ neue Analysen, die das konsistente klinische Profil von Vutrisiran bei ATTR-CM unterstreichen • Business Wire • 05/05/2026 12:39:00 AM
- Alnylam présentera de nouvelles analyses lors du congrès Heart Failure 2026, soulignant le profil clinique constant du vutrisiran dans l’ATTR-CM • Business Wire • 05/05/2026 12:39:00 AM
- Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM • Business Wire • 05/04/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/30/2026 12:16:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 12:04:14 PM
- Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress • Business Wire • 04/30/2026 12:00:00 PM
- When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech • InvestorsHub NewsWire • 04/20/2026 01:00:00 PM
- When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results • Business Wire • 04/16/2026 12:00:00 PM

